By: InvestorBrandNetwork (IBN)
October 8, 2025
Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability
- Oncotelic Therapeutics developed the Deciparticles(TM) technology to improve the bioavailability of drugs, largely thanks to the creation of sub-20nm size of the nanoparticles
- Sapu Nano, part of Oncotelic’s GMP Bio joint venture, receives clearance to begin Phase 1 trial of Sapu003, an injectable form of Everolimus (Afinitor(R)) for breast cancer
- In preclinical studies, Sapu003 could raise the bioavailability of Everolimus (Afinitor(R)) from around 10%, as oral pill, up to anywhere from 80 to 100%, as injectable
- Result hopes for higher bioavailability in that drugs may have dramatically better, faster, and more consistent efficacy for patients
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company advancing a diversified pipeline spanning oncology, immunotherapy, neurodegeneration, and rare diseases. In a recent interview on the BioMedWire podcast, Chairman and CEO Dr. Vuong Trieu emphasized the company’s unique model: focusing on de-risked, late-stage assets and accelerating their development through regulatory pathways designed for speed and efficiency.
The technology, called Deciparticles(TM), is being developed by Sapu Nano, a member of the Sapu family of companies, which is established through GMP Biotechnology Limited, which itself is a joint venture between Oncotelic Therapeutics and Dragon Overseas Capital Limited. This technology enabled…
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability.
